These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 16626720)

  • 1. ACAT inhibitor pactimibe sulfate (CS-505) reduces and stabilizes atherosclerotic lesions by cholesterol-lowering and direct effects in apolipoprotein E-deficient mice.
    Terasaka N; Miyazaki A; Kasanuki N; Ito K; Ubukata N; Koieyama T; Kitayama K; Tanimoto T; Maeda N; Inaba T
    Atherosclerosis; 2007 Feb; 190(2):239-47. PubMed ID: 16626720
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Importance of acyl-coenzyme A:cholesterol acyltransferase 1/2 dual inhibition for anti-atherosclerotic potency of pactimibe.
    Kitayama K; Tanimoto T; Koga T; Terasaka N; Fujioka T; Inaba T
    Eur J Pharmacol; 2006 Jul; 540(1-3):121-30. PubMed ID: 16730694
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pactimibe stabilizes atherosclerotic plaque through macrophage acyl-CoA:cholesterol acyltransferase inhibition in WHHL rabbits.
    Kitayama K; Koga T; Maeda N; Inaba T; Fujioka T
    Eur J Pharmacol; 2006 Jun; 539(1-2):81-8. PubMed ID: 16690054
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acyl-CoA:cholesterol acyltransferase inhibitor avasimibe reduces atherosclerosis in addition to its cholesterol-lowering effect in ApoE*3-Leiden mice.
    Delsing DJ; Offerman EH; van Duyvenvoorde W; van Der Boom H; de Wit EC; Gijbels MJ; van Der Laarse A; Jukema JW; Havekes LM; Princen HM
    Circulation; 2001 Apr; 103(13):1778-86. PubMed ID: 11282910
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Direct effect of an acyl-CoA:cholesterol acyltransferase inhibitor, F-1394, on atherosclerosis in apolipoprotein E and low density lipoprotein receptor double knockout mice.
    Chiwata T; Aragane K; Fujinami K; Kojima K; Ishibashi S; Yamada N; Kusunoki J
    Br J Pharmacol; 2001 Aug; 133(7):1005-12. PubMed ID: 11487509
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The ACAT inhibitor avasimibe reduces macrophages and matrix metalloproteinase expression in atherosclerotic lesions of hypercholesterolemic rabbits.
    Bocan TM; Krause BR; Rosebury WS; Mueller SB; Lu X; Dagle C; Major T; Lathia C; Lee H
    Arterioscler Thromb Vasc Biol; 2000 Jan; 20(1):70-9. PubMed ID: 10634802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacology of the ACAT inhibitor avasimibe (CI-1011).
    Llaverías G; Laguna JC; Alegret M
    Cardiovasc Drug Rev; 2003; 21(1):33-50. PubMed ID: 12595916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Statin therapy alone and in combination with an acyl-CoA:cholesterol O-acyltransferase inhibitor on experimental atherosclerosis.
    Worthley SG; Helft G; Corti R; Worthley MI; Chew DP; Fayad ZA; Zaman AG; Fallon JT; Fuster V; Badimon JJ
    Pathophysiol Haemost Thromb; 2007; 36(1):9-17. PubMed ID: 18332609
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiple mechanisms of hypocholesterolemic action of pactimibe, a novel acyl-coenzyme A:cholesterol acyltransferase inhibitor.
    Kitayama K; Koga T; Inaba T; Fujioka T
    Eur J Pharmacol; 2006 Aug; 543(1-3):123-32. PubMed ID: 16814766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acyl-CoA:cholesterol acyltransferase inhibition reduces atherosclerosis in apolipoprotein E-deficient mice.
    Kusunoki J; Hansoty DK; Aragane K; Fallon JT; Badimon JJ; Fisher EA
    Circulation; 2001 May; 103(21):2604-9. PubMed ID: 11382731
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A selective ACAT-1 inhibitor, K-604, stimulates collagen production in cultured smooth muscle cells and alters plaque phenotype in apolipoprotein E-knockout mice.
    Yoshinaka Y; Shibata H; Kobayashi H; Kuriyama H; Shibuya K; Tanabe S; Watanabe T; Miyazaki A
    Atherosclerosis; 2010 Nov; 213(1):85-91. PubMed ID: 20843517
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tomatidine, a tomato sapogenol, ameliorates hyperlipidemia and atherosclerosis in apoE-deficient mice by inhibiting acyl-CoA:cholesterol acyl-transferase (ACAT).
    Fujiwara Y; Kiyota N; Tsurushima K; Yoshitomi M; Horlad H; Ikeda T; Nohara T; Takeya M; Nagai R
    J Agric Food Chem; 2012 Mar; 60(10):2472-9. PubMed ID: 22224814
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravascular ultrasound assessment of novel antiatherosclerotic therapies: rationale and design of the Acyl-CoA:Cholesterol Acyltransferase Intravascular Atherosclerosis Treatment Evaluation (ACTIVATE) Study.
    Nicholls SJ; Sipahi I; Schoenhagen P; Wisniewski L; Churchill T; Crowe T; Goormastic M; Wolski K; Tuzcu EM; Nissen SE;
    Am Heart J; 2006 Jul; 152(1):67-74. PubMed ID: 16824833
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of low dose atorvastatin versus diet-induced cholesterol lowering on atherosclerotic lesion progression and inflammation in apolipoprotein E*3-Leiden transgenic mice.
    Verschuren L; Kleemann R; Offerman EH; Szalai AJ; Emeis SJ; Princen HM; Kooistra T
    Arterioscler Thromb Vasc Biol; 2005 Jan; 25(1):161-7. PubMed ID: 15514207
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A selective ACAT-1 inhibitor, K-604, suppresses fatty streak lesions in fat-fed hamsters without affecting plasma cholesterol levels.
    Ikenoya M; Yoshinaka Y; Kobayashi H; Kawamine K; Shibuya K; Sato F; Sawanobori K; Watanabe T; Miyazaki A
    Atherosclerosis; 2007 Apr; 191(2):290-7. PubMed ID: 16820149
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New pyripyropene A derivatives, highly SOAT2-selective inhibitors, improve hypercholesterolemia and atherosclerosis in atherogenic mouse models.
    Ohshiro T; Ohtawa M; Nagamitsu T; Matsuda D; Yagyu H; Davis MA; Rudel LL; Ishibashi S; Tomoda H
    J Pharmacol Exp Ther; 2015 Nov; 355(2):299-307. PubMed ID: 26338984
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ACAT inhibition and progression of carotid atherosclerosis in patients with familial hypercholesterolemia: the CAPTIVATE randomized trial.
    Meuwese MC; de Groot E; Duivenvoorden R; Trip MD; Ose L; Maritz FJ; Basart DC; Kastelein JJ; Habib R; Davidson MH; Zwinderman AH; Schwocho LR; Stein EA;
    JAMA; 2009 Mar; 301(11):1131-9. PubMed ID: 19293413
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel indoline-based acyl-CoA: cholesterol acyltransferase inhibitor: Effects of introducing a methanesulfonamide group on physicochemical properties and biological activities.
    Shoji Y; Takahashi K; Ohta M; Kasai M; Kunishiro K; Kanda M; Yogai S; Takeuchi Y; Shirahase H
    Bioorg Med Chem; 2009 Aug; 17(16):6020-31. PubMed ID: 19608421
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disodium ascorbyl phytostanyl phosphate reduces plasma cholesterol concentrations and atherosclerotic lesion formation in apolipoprotein E-deficient mice.
    Lukic T; Wasan KM; Zamfir D; Moghadasian MH; Pritchard PH
    Metabolism; 2003 Apr; 52(4):425-31. PubMed ID: 12701053
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic infusion of salusin-alpha and -beta exerts opposite effects on atherosclerotic lesion development in apolipoprotein E-deficient mice.
    Nagashima M; Watanabe T; Shiraishi Y; Morita R; Terasaki M; Arita S; Hongo S; Sato K; Shichiri M; Miyazaki A; Hirano T
    Atherosclerosis; 2010 Sep; 212(1):70-7. PubMed ID: 20684826
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.